EastGate Acquisitions Corporation with locations in Salt Lake City, Utah and Toronto, Canada, is a pharmaceutical company aimed at utilizing drug delivery innovations for developing of improved novel formulations and alternative dosage forms of existing biologically active molecules.
The Company's model is based on a two-tier business approach that includes development of novel pharmaceutical products and innovative dietary supplements. Both pharmaceutical products and natural supplements are developed using highly effective contemporary technologies and demonstrated already proven usefulness in improvement of bioavailability and biological action of incorporated molecules.
The Company's product candidates address various pharmaceutical markets, including neurological disorders, such as epilepsy and panic attacks, infectious diseases and diabetes. Our natural dietary supplements, also an integral part of our R&D program, include compositions for glucose regulations, urinary tract health improvement, enhanced vitamin delivery and skin conditions.
EastGate is working to expand its current product portfolio through targeted investments in pharmaceutical research and development. We are working closely with clinicians and patient advocate groups worldwide to identify existing health issues where EastGate's approach will be most beneficial for patient care.
For more information, please visit the company's website at: www.EastGatePharmaceuticals.com.
Website: http://www.eastgatebiotech.com/
Share Structure
| | Market Value1 | $2,140,172 | a/o Apr 19, 2017 |
 | Authorized Shares | 450,000,000 | a/o Mar 30, 2017 |
| Outstanding Shares | 214,017,177 | a/o Mar 30, 2017 |
ETBI patents: US 61/947,678 Title: Pharmaceutical Composition for Transmucosal Delivery US 61/947,698 Title: Treatment of Diabetes and Metabolic Syndrome PCT/C2014/000126 Title: Pharmaceutical Composition for Transmucosal Administration of Benzodiazepines PCT/CA2014/000127 Title: Pharmaceutical Composition For Enhanced Transmucosal Administration of Benzodiazepines PRESS RELEASES
http://www.eastgatebiotech.com/investors/press-releases/eastgate-biotech-business-turnaround-expert-bill-abajian-positive-stocks-investor-influence-network/ http://www.eastgatebiotech.com/investors/press-releases/eastgate-biotech-corp-engages-gunpowder-capital-corp/ http://www.eastgatebiotech.com/investors/press-releases/dr-ishaan-sundar-medical-director/ CHART
